TNF and cancer: The multivariable Cox regression analyses on site-specific cancer in the before-matching cohort found adjusted HRs (95% CIs) in the TNF inhibitor users were significantly lower than in the nbDMARD users for gastrointestinal (adjusted HR, 0.432; 95% CI, 0.235–0.797), breast (adjusted HR, 0.146; 95% CI, 0.045–0.474), and genitourinary (adjusted HR, 0.220; 95% CI, 0.059–0.820) cancers.